Waterstone Consulting

Waterstone Pharmaceuticals is a specialty pharmaceutical company and contract development and manufacturing organization (CDMO) focused on the development of innovative therapies for liver and metabolic diseases. The company maintains a dual business model, leveraging its internal R&D pipeline alongside its manufacturing capabilities to provide integrated services from drug discovery to commercial production. Waterstone's primary therapeutic focus includes chronic hepatitis B (HBV) and non-alcoholic steatohepatitis (NASH). Headquartered in Wuhan, China, with operations in the United States, the company utilizes its proprietary technology platforms to develop small molecule drugs. Its CDMO division serves global pharmaceutical clients, providing high-quality API and formulation development.